itamin D Analogs : Actions and Role in the reatment of Secondary Hyperparathyroidism
暂无分享,去创建一个
[1] M. Fukagawa,et al. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] M. Wolf,et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. , 2003, The New England journal of medicine.
[3] T. Akiba,et al. Multicenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] E. Slatopolsky,et al. Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] Y. Ohashi,et al. Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] H. Mann,et al. Alfacalcidol in the therapy of renal bone disease. , 2001, International journal of clinical pharmacology and therapeutics.
[7] D. Batlle,et al. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] J. Valdin,et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. , 2001, Clinical nephrology.
[9] Keith C. Norris,et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[10] Keith C. Norris,et al. Intermittent doxercalciferol (1α-Hydroxyvitamin D2) therapy for secondary hyperparathyroidism , 2000 .
[11] T Saruta,et al. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] L. Avioli. Vitamin D and the D-Hormones, Alfacalcidol and Calcitriol, as Therapeutic Agents for Osteoporotic Populations , 1999, Calcified Tissue International.
[13] E. Slatopolsky,et al. Vitamin D Analogs: Perspectives for Treatment , 1999, Mineral and Electrolyte Metabolism.
[14] E. Slatopolsky,et al. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. , 1999, Journal of the American Society of Nephrology : JASN.
[15] H. Malluche,et al. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. , 1999, Kidney international.
[16] L. Hamm,et al. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] Y. Ohashi,et al. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[18] E. Mawer,et al. Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans: 24-hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum. , 1998, The Journal of clinical endocrinology and metabolism.
[19] A. Dusso,et al. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] E. Slatopolsky,et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[21] J. Kanis,et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure , 1995, BMJ.
[22] T. Cundy,et al. A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism. , 1994, Journal of the American Society of Nephrology : JASN.
[23] B. Carroll,et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. , 1994, Kidney international.
[24] T. Kobayashi,et al. The binding properties, with blood proteins, and tissue distribution of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a noncalcemic analogue of 1 alpha, 25-dihydroxyvitamin D3, in rats. , 1994, Journal of biochemistry.
[25] J. Delmez,et al. Pathogenesis of secondary hyperparathyroidism. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[26] J. Delmez,et al. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] T. Mori,et al. On the mechanisms for the selective action of vitamin D analogs. , 1991, Endocrinology.
[28] T. Kobayashi,et al. Protein-binding properties of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a synthetic analogue of 1 alpha,25-dihydroxyvitamin D3. , 1989, Journal of nutritional science and vitaminology.
[29] Keith C. Norris,et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. , 1989, The New England journal of medicine.
[30] G. Hendy,et al. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. , 1989, Endocrinology.
[31] J. Russell,et al. Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. , 1986, Endocrinology.
[32] J. Silver,et al. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. , 1986, The Journal of clinical investigation.
[33] J. Russell,et al. 1,25-Dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. , 1985, Endocrinology.
[34] H. Harter,et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. , 1984, The Journal of clinical investigation.
[35] H. DeLuca,et al. Antirachitic Activity of 1α-Hydroxyergocalciferol and 1α-Hydroxycholecalciferol in Rats , 1984 .
[36] F. Marsh,et al. Long-term experience of alfacalcidol in renal osteodystrophy. , 1982, The Quarterly journal of medicine.
[37] A. Dusso,et al. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[38] A. Yoshitake,et al. In vivo and in vitro pharmacokinetics and metabolism studies of 26,26,26,27,27,27-F6-1,25(OH)2 vitamin D3 (Falecalcitriol) in rat: induction of vitamin D3-24-hydroxylase (CYP24) responsible for 23S-hydroxylation in target tissues and the drop in serum levels. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[39] K. Martin,et al. Renal osteodystrophy: pathogenesis and management. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.